Clinical, Morphological and Functional Aspects in Myocarditis.

Sponsor
University of Messina (Other)
Overall Status
Completed
CT.gov ID
NCT04217876
Collaborator
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy (Other), Humanitas Hospital, Italy (Other), Vannini Hospital Rome (Other)
200
4
36
50
1.4

Study Details

Study Description

Brief Summary

Cardiac magnetic resonance (CMR) is accurate to identify acute myocardial damage (edema, hyperemia, and/or fibrosis) due to acute myocarditis (AM). Recently, two-dimensional strain echocardiography was also validated in order to provide important information on myocardial dysfunction in patients with AM, even if no wall motion abnormalities are detected. No data are available about incidence of longitudinal myocardial dysfunction and its prognostic role in AM.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: post-processing analysis of cardiac imaging (strain echocardiography)

Detailed Description

In this study, the investigators will analyze the effect of acute myocarditis-induced damage on LV myocardial deformation and remodeling both in the acute myocarditis phase and follow-up period (about 2 years later). The investigators will use a combined approach including strain echocardiography to asses left ventricular myocardial deformation and late gadolinium enhancement (LGE)cardiac magnetic resonance for the assessment of left ventricular damage.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Clinical, Morphological and Functional Aspects in Acute and Chronic Myocarditis.
Actual Study Start Date :
Dec 1, 2016
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Clinically suspected infarct-like acute myocarditis

Diagnosis of infarct-like AM was based on five criteria: (a) history of flu-like symptoms within 8 weeks prior admission; (b) new onset of symptoms such as fatigue/breathlessness, chest pain, mild dyspnea, and/or palpitation; (c) ischemic ECG pattern (ST-segment elevation and/or T-wave anomalies); (d) increase of inflammatory markers (non-high- sensitivity CRP > 8 mg/L and/or white blood cell count > 11.000/mm3) and cardiac enzymes; and (e) preserved global systolic function (EF > 50%). We excluded patients with New York Heart Association (NYHA) functional heart classifications II-IV, LVEF < 50% and those patients with electrocardiographic evidence of bradyarrhythmias (≥second-degree atrioventricular block) or tachyarrhythmias (ventricular or supraventricular arrhythmias).

Diagnostic Test: post-processing analysis of cardiac imaging (strain echocardiography)
A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment. The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion.

Outcome Measures

Primary Outcome Measures

  1. Demonstrating incidence of longitudinal dysfunction of left ventricle in patients with acute myocarditis and preserved ejection fraction. [Day 0]

    Longitudinal systolic function (s-1) of the left ventricle will be measured (%) by echocardiography.

  2. Demonstrating effect of myocarditis damage due to myocardial fibrosis on longitudinal function. [Day 0]

    Longitudinal systolic function (s-1) of the left ventricle will be measured (%) by echocardiography. Myocardial fibrosis LGE was defined as myocardium with an signal intensity higher than the average signal intensity of the region of interest more than 6 standard deviation in late gadolinium enhancement technique.

Secondary Outcome Measures

  1. Prognostic role of longitudinal dyfunction. [from 6-60 months]

    cardiac death, resuscitated cardiac arrest, ventricular assist device implantation, cardiac transplantation, appropriate implantable cardioverter defibrillator (ICD) shock, relapse of AM and hospitalization for worsening heart failure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosis of clinical suspected acute myocarditis (AM)

  • diagnosis of AM with cardiac magnetic resonance (CMR) according to Lake Louise criteria (myocardial edema, hyperemia, and LGE).

  • absence of coronary artery diseases confirmed by coronary angiography or computed tomography in all patients with the exception of those younger than 30 years with a low risk of coronary artery disease.

Exclusion Criteria:
  • Previous heart diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lorenzo Monti Milan Italy 20089
2 Alessandro Pingitore Pisa Italy 56126
3 Giovanni D Aquaro Pisa Italy
4 Giovanni Camastra Roma Italy 00177

Sponsors and Collaborators

  • University of Messina
  • Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
  • Humanitas Hospital, Italy
  • Vannini Hospital Rome

Investigators

  • Principal Investigator: Gianluca Di Bella, University of Messina, Italy
  • Study Chair: Mariapaola Campisi, MD, University of Messina, Italy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gianluca Di Bella, Associate Professor Cardiovascular Diseases, University of Messina
ClinicalTrials.gov Identifier:
NCT04217876
Other Study ID Numbers:
  • 11616
First Posted:
Jan 6, 2020
Last Update Posted:
Jan 6, 2020
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gianluca Di Bella, Associate Professor Cardiovascular Diseases, University of Messina
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 6, 2020